|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product | |||||
| Total revenues | |||||
| Cost of revenues | |||||
| Service and Other | |||||
| Total cost of revenues | |||||
| Gross profit | |||||
| Operating expenses | |||||
| Loss on impairment of goodwill | |||||
| Selling, general and administrative | |||||
| Restructuring costs | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| Loss on impairment of intangible assets | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other income (expenses), net | |||||
| Interest income | |||||
| Interest expense | |||||
| Service | |||||
| Nonrelated Party | |||||
| Related Party | |||||
| Change in fair value of royalties payable due to related parties | |||||
| Change in fair value of convertible notes payable | |||||
| Loss on debt extinguishment | |||||
| Net loss on trading debt securities | |||||
| Other expenses, net | |||||
| Change in fair value of royalties payable | |||||
| Total other income (expenses), net | |||||
| Loss from operations before income tax provision (benefit) | |||||
| Income tax provision (benefit) | |||||
| Net loss | |||||
| Less: Net loss attributable to non-controlling interest | |||||
| Net loss attributable to Catheter Precision, Inc. | |||||
| Deemed dividend - warrant inducement offer | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share attributable to common stockholders, basic and diluted | |||||
| Weighted average common shares used in computing net loss per share, basic and diluted | |||||
| Net loss attributable to Catheter Precision, Inc. common stockholders | |||||
| Net loss per share attributable to Catheter Precision, Inc. common stockholders, basic and diluted (in dollars per share) | |||||
| Weighted-average common shares used in computing net loss per share, basic and diluted (in shares) | |||||
Loading...